2257 — Sirnaomics Share Price
Last trade - 00:00- HK$784.36m
- HK$627.02m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.5 | ||
| Price to Tang. Book | 2.55 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -133.82% | ||
| Return on Equity | -97.03% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 1.83 | 70.09 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sirnaomics Ltd. is an investment holding company. The Company and its subsidiaries are clinical-stage biotechnology companies that are engaged in developing and commercializing ribonucleic acid interference (RNAi) technology and multiple therapeutics. The Company is engaged in discovering and developing drugs for indications with unmet medical needs in areas. Its lead clinical drug candidates include STP705 and STP707. Its STP705 is a sterile drug product for the treatment of nonmelanoma skin cancer (NMSC), including squamous cell carcinoma in situ and basal cell carcinoma (BCC), recurrent keloids after keloidectomy, hypertrophic scar (HTS) and solid liver tumors, as well as for medical aesthetics. Its STP707 is a sterile drug product for the treatment of solid tumors, including liver cancer, metastatic cutaneous squamous-cell skin cancer (cSCC) and non-small cell lung cancer. It is capitalizing on its dual delivery platforms, which include Polypeptide nanoparticle (PNP) and GalAhead.
Directors
- Yang Lu CHM (66)
- George Ji COO
- Dmitry Samarsky CTO
- David Evans CSO (59)
- Wing Kei Yip VPR (35)
- Michael Molyneaux EDR (51)
- Zhifeng Long OTH (59)
- Yongxiang Wang OTH (69)
- Ting Cheung Leung SEC (38)
- Yun Zhang SEC (36)
- Xiaochang Dai NED (58)
- Mincong Huang NED (33)
- Jiajun Lai NED (33)
- Da Liu NED (51)
- Jiankang Zhang NED (64)
- Fengmao Hua NID (53)
- Monin Ung NID (53)
- Cheung Hoi Yu NID (67)
- Shing Mo Han Yvonne Law NID (66)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 12th, 2007
- Public Since
- December 30th, 2021
- No. of Employees
- 145
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 87,638,480
- Address
- 401 Professional Drive, Suite 280, GAITHERSBURG, 20879
- Web
- https://www.sirnaomics.com/
- Phone
- Auditors
- Deloitte Touche Tohmatsu
Upcoming Events for 2257
Similar to 2257
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:19 UTC, shares in Sirnaomics are trading at HK$8.95. This share price information is delayed by 15 minutes.
Shares in Sirnaomics last closed at HK$8.95 and the price had moved by -81.92% over the past 365 days. In terms of relative price strength the Sirnaomics share price has underperformed the FTSE Developed Asia Pacific Index by -83.13% over the past year.
The overall consensus recommendation for Sirnaomics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Sirnaomics does not currently pay a dividend.
Sirnaomics does not currently pay a dividend.
Sirnaomics does not currently pay a dividend.
To buy shares in Sirnaomics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$8.95, shares in Sirnaomics had a market capitalisation of HK$784.36m.
Here are the trading details for Sirnaomics:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2257
Based on an overall assessment of its quality, value and momentum Sirnaomics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Sirnaomics is HK$72.00. That is 704.52% above the last closing price of HK$8.95.
Analysts covering Sirnaomics currently have a consensus Earnings Per Share (EPS) forecast of -$1.76 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sirnaomics. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -82.76%.
As of the last closing price of HK$8.95, shares in Sirnaomics were trading -73.87% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sirnaomics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$8.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Sirnaomics' management team is headed by:
- Yang Lu - CHM
- George Ji - COO
- Dmitry Samarsky - CTO
- David Evans - CSO
- Wing Kei Yip - VPR
- Michael Molyneaux - EDR
- Zhifeng Long - OTH
- Yongxiang Wang - OTH
- Ting Cheung Leung - SEC
- Yun Zhang - SEC
- Xiaochang Dai - NED
- Mincong Huang - NED
- Jiajun Lai - NED
- Da Liu - NED
- Jiankang Zhang - NED
- Fengmao Hua - NID
- Monin Ung - NID
- Cheung Hoi Yu - NID
- Shing Mo Han Yvonne Law - NID